{
  "abstract": "Introduction: Despite their benefit, current anti-EGFR therapies are limited by narrow efficacy profiles due to dose-limiting toxicities. This phase 2 open-label study evaluated the efficacy and safety of ABT-806, an EGFR-targeting antibody that is tumor specific, in patients with advanced EGFR-expressing tumors including head and neck cancers (H&NC) and squamous cell carcinoma (SCC) of other sites. Methods: Patients with advanced H&NC (cohort A) or SCC of other sites (cohort B) were enrolled in the study. ABT-806 was administered as monotherapy at a dose of 24 mg/kg intravenously using a twice weekly dosing schedule until unacceptable toxicity and/or evidence of disease progression. Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0; tumor response was assessed using the Response Evaluation criteria in Solid Tumors v1.1. EGFR status was assessed with mAb806 and EGFRvIII immunohistochemistry and correlated with outcomes. Results: ABT-806 was well tolerated with no grade 3+ treatment-related AEs. Disease stabilization was observed in two patients (14%) and for a median duration of 19.5 weeks. This included one patient from cohort A and one patient from cohort B. Progression-free survival and overall survival was not significantly different between the two cohorts. Conclusions: Although clinical activity was limited in this small, heavily pre-treated, and biomarker-unselected population, ABT-806 demonstrated an excellent safety profile with minimal classical EGFR-related toxicity. These findings support the development of more tumor-specific EGFR antibodies for use, particularly in combinatorial regimens.",
  "abstract_shown": true,
  "affiliations": [
    "Medical Oncology, Austin Hospital, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australia",
    "Tumor Targeting Program, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia",
    "School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia",
    "Oncology Discovery, AbbVie Inc., North Chicago, IL 60064, USA",
    "Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC 3084, Australia",
    "Faculty of Medicine, Melbourne University, Melbourne, VIC 3010, Australia"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Hui K. Gan"
    },
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Sagun Parakh",
      "orcid": "0000-0003-3891-2489"
    },
    {
      "affs": [
        0
      ],
      "name": "Malaka Ameratunga",
      "orcid": "0000-0002-7171-6781"
    },
    {
      "affs": [
        0
      ],
      "name": "Anis Hamid"
    },
    {
      "affs": [
        0
      ],
      "name": "George Iatropoulos"
    },
    {
      "affs": [
        0
      ],
      "name": "Michelle Beecher"
    },
    {
      "affs": [
        1
      ],
      "name": "Diana Cao"
    },
    {
      "affs": [
        1
      ],
      "name": "Kerryn Westcott"
    },
    {
      "affs": [
        0
      ],
      "name": "Jaren Caine"
    },
    {
      "affs": [
        1
      ],
      "name": "Jodie Palmer",
      "orcid": "0000-0002-8964-0965"
    },
    {
      "affs": [
        3
      ],
      "name": "Edward B. Reilly"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Fiona E. Scott",
      "orcid": "0009-0003-3190-6518"
    },
    {
      "affs": [
        1,
        2,
        4,
        5
      ],
      "name": "Andrew M. Scott"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bvxxxc1vyjqxk.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18203313",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702275/?tool=EBI",
  "id": "bvxxxc1vyjqxk",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/20/3313",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|HER2/EGFR in Cancer Research"
    ]
  ],
  "openalex": "W7221747251",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702275/pdf/?tool=EBI",
  "pmcid": "PMC13702275",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/bvxxxc1vyjqxk.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18203313",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/20/3313"
    },
    {
      "first_seen": "2026-10-30T12:21:47Z",
      "native_id": "PMC:PMC13702275",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13702275"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|HER2/EGFR in Cancer Research",
      "subfield": "oncology"
    }
  ],
  "title": "An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas",
  "title_text": "An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:47Z",
  "url": "https://research.draconitic.com/paper/bvxxxc1vyjqxk",
  "venue": "Cancers",
  "versions": []
}